These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 22193629)

  • 1. Impact of novel oncolytic virus HF10 on cellular components of the tumor microenviroment in patients with recurrent breast cancer.
    Sahin TT; Kasuya H; Nomura N; Shikano T; Yamamura K; Gewen T; Kanzaki A; Fujii T; Sugae T; Imai T; Nomoto S; Takeda S; Sugimoto H; Kikumori T; Kodera Y; Nishiyama Y; Nakao A
    Cancer Gene Ther; 2012 Apr; 19(4):229-37. PubMed ID: 22193629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
    Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F
    Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pilot study of oncolytic viral therapy using mutant herpes simplex virus (HF10) against recurrent metastatic breast cancer.
    Kimata H; Imai T; Kikumori T; Teshigahara O; Nagasaka T; Goshima F; Nishiyama Y; Nakao A
    Ann Surg Oncol; 2006 Aug; 13(8):1078-84. PubMed ID: 16865590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic virotherapy with an HSV amplicon vector expressing granulocyte-macrophage colony-stimulating factor using the replication-competent HSV type 1 mutant HF10 as a helper virus.
    Kohno SI; Luo C; Nawa A; Fujimoto Y; Watanabe D; Goshima F; Tsurumi T; Nishiyama Y
    Cancer Gene Ther; 2007 Nov; 14(11):918-26. PubMed ID: 17693992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncolytic viral therapy for breast cancer with herpes simplex virus type 1 mutant HF 10.
    Teshigahara O; Goshima F; Takao K; Kohno S; Kimata H; Nakao A; Nishiyama Y
    J Surg Oncol; 2004 Jan; 85(1):42-7. PubMed ID: 14696086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination therapy of oncolytic herpes simplex virus HF10 and bevacizumab against experimental model of human breast carcinoma xenograft.
    Tan G; Kasuya H; Sahin TT; Yamamura K; Wu Z; Koide Y; Hotta Y; Shikano T; Yamada S; Kanzaki A; Fujii T; Sugimoto H; Nomoto S; Nishikawa Y; Tanaka M; Tsurumaru N; Kuwahara T; Fukuda S; Ichinose T; Kikumori T; Takeda S; Nakao A; Kodera Y
    Int J Cancer; 2015 Apr; 136(7):1718-30. PubMed ID: 25156870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncolytic virotherapy for malignant melanoma with herpes simplex virus type 1 mutant HF10.
    Watanabe D; Goshima F; Mori I; Tamada Y; Matsumoto Y; Nishiyama Y
    J Dermatol Sci; 2008 Jun; 50(3):185-96. PubMed ID: 18226503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I Dose-escalation Clinical Trial of HF10 Oncolytic Herpes Virus in 17 Japanese Patients with Advanced Cancer.
    Kasuya H; Kodera Y; Nakao A; Yamamura K; Gewen T; Zhiwen W; Hotta Y; Yamada S; Fujii T; Fukuda S; Tsurumaru N; Kuwahara T; Kikumori T; Koide Y; Fujimoto Y; Nakashima T; Hirooka Y; Shiku H; Tanaka M; Takesako K; Kondo T; Aleksic B; Kawashima H; Goto H; Nishiyama Y
    Hepatogastroenterology; 2014 May; 61(131):599-605. PubMed ID: 26176043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant treatment of hepatic malignancy: an oncolytic herpes simplex virus expressing IL-12 effectively treats the parent tumor and protects against recurrence-after resection.
    Jarnagin WR; Zager JS; Klimstra D; Delman KA; Malhotra S; Ebright M; Little S; DeRubertis B; Stanziale SF; Hezel M; Federoff H; Fong Y
    Cancer Gene Ther; 2003 Mar; 10(3):215-23. PubMed ID: 12637943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intratumoral injection of herpes simplex virus HF10 in recurrent head and neck squamous cell carcinoma.
    Fujimoto Y; Mizuno T; Sugiura S; Goshima F; Kohno S; Nakashima T; Nishiyama Y
    Acta Otolaryngol; 2006 Oct; 126(10):1115-7. PubMed ID: 16923721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Herpes simplex virus type 1 mutant HF10 oncolytic viral therapy for bladder cancer.
    Kohno S; Luo C; Goshima F; Nishiyama Y; Sata T; Ono Y
    Urology; 2005 Nov; 66(5):1116-21. PubMed ID: 16286150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncolytic herpes simplex virus treatment of metastatic breast cancer.
    Wang J; Hu P; Zeng M; Rabkin SD; Liu R
    Int J Oncol; 2012 Mar; 40(3):757-63. PubMed ID: 22108767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene-viral cancer therapy using dual-regulated oncolytic adenovirus with antiangiogenesis gene for increased efficacy.
    Su C; Na M; Chen J; Wang X; Liu Y; Wang W; Zhang Q; Li L; Long J; Liu X; Wu M; Fan X; Qian Q
    Mol Cancer Res; 2008 Apr; 6(4):568-75. PubMed ID: 18344493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination treatment of human pancreatic cancer xenograft models with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib and oncolytic herpes simplex virus HF10.
    Yamamura K; Kasuya H; Sahin TT; Tan G; Hotta Y; Tsurumaru N; Fukuda S; Kanda M; Kobayashi D; Tanaka C; Yamada S; Nakayama G; Fujii T; Sugimoto H; Koike M; Nomoto S; Fujiwara M; Tanaka M; Kodera Y
    Ann Surg Oncol; 2014 Feb; 21(2):691-8. PubMed ID: 24170435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncolytic viral therapy with a combination of HF10, a herpes simplex virus type 1 variant and granulocyte-macrophage colony-stimulating factor for murine ovarian cancer.
    Goshima F; Esaki S; Luo C; Kamakura M; Kimura H; Nishiyama Y
    Int J Cancer; 2014 Jun; 134(12):2865-77. PubMed ID: 24265099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Oncolytic virotherapy using replication-competent herpes simplex viruses].
    Nishiyama Y; Goshima F
    Uirusu; 2007 Jun; 57(1):57-65. PubMed ID: 18040155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishment of a novel foreign gene delivery system combining an HSV amplicon with an attenuated replication-competent virus, HSV-1 HF10.
    Zhang L; Daikoku T; Ohtake K; Ohtsuka J; Nawa A; Kudoh A; Iwahori S; Isomura H; Nishiyama Y; Tsurumi T
    J Virol Methods; 2006 Nov; 137(2):177-83. PubMed ID: 16854473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective treatment of disseminated peritoneal colon cancer with new replication-competent herpes simplex viruses.
    Kimata H; Takakuwa H; Goshima F; Teshigahara O; Nakao A; Kurata T; Sata T; Nishiyama Y
    Hepatogastroenterology; 2003; 50(52):961-6. PubMed ID: 12845959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Novel treatment with oncolytic herpes simplex virus, 'HF10' against breast cancer].
    Kimata H; Teshigahara O; Nishiyama Y; Nakao A
    Nihon Rinsho; 2004 May; 62(5):987-93. PubMed ID: 15148832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical experiment of mutant herpes simplex virus HF10 therapy for cancer.
    Nakao A; Takeda S; Shimoyama S; Kasuya H; Kimata H; Teshigahara O; Sawaki M; Kikumori T; Kodera Y; Nagasaka T; Goshima F; Nishiyama Y; Imai T
    Curr Cancer Drug Targets; 2007 Mar; 7(2):169-74. PubMed ID: 17346108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.